Klebsiella pneumoniae (ATCC 43816), IC Lung Infection Model, LD90-100

  1. image
  2. image
  3. image
  4. image
CONTACT CUSTOMER SERVICE
  ADD TO FAVORITES
  ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
RELATED SERVICES
RELATED PRODUCTS
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model assesses the efficacy of test articles for protection against a lethal infection in the lung via intranasal inoculation. It may be used to evaluate small molecules, biologics and vaccines. Microbial counts in the infected lung tissue can be measured
SPECIES
Klebsiella pneumoniae
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
SOURCE
STRAIN SOURCE
American Type Culture Collection (ATCC)
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 10 male or female specific-pathogen-free BALB/c weighing 18 ± 2 g are used. Each immunocompetent (IC) animal is inoculated intranasally (0.02 mL/mouse) with an LD90-100 dose (1-3 x 10^5 CFU) of Klebsiella pneumoniae (ATCC 43816) suspended in PBS. Vehicle and/or test substances are then administered 1 and 13 hours later (BID) or per client’s specifications. Standard dose routes are IV, IP, SC or PO. Mortality is recorded daily during the following 7 days. Prevention of mortality is recorded in percentage and the significance is assessed by Fisher’s exact test. For bacterial enumeration (optional service), the animals are euthanized with CO2 asphyxiation at 25 h post-infection, and the lung tissue is harvested from each of the test animals. The removed lung tissues are homogenized in 1 mL PBS, pH 7.4, with a Polytron homogenizer. Homogenates, 0.1 mL, are diluted 10-fold and plated on MacConkey II agar for colony count (CFU/g) determination.
CRITERIA FOR SIGNIFICANCE
≥ 50% of survival
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

 

© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences